Progression of Hodgkin lymphoma and plasma cell neoplasms: Report from the 2021 SH/EAHP Workshop
CONCLUSIONS: Better molecular characterization of both of these neoplasms and mechanisms of progression will help us to better understand mechanisms of progression and perhaps develop better prognostic models, as well as identifying novel therapeutic targets.PMID:37085150 | DOI:10.1093/ajcp/aqad023 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - April 21, 2023 Category: Cancer & Oncology Authors: Reza Nejati Catalina Amador Magdalena Czader Elizabeth Thacker Devang Thakkar Sandeep S Dave Ahmet Dogan Amy Duffield John R Goodlad German Ott Mariusz A Wasik Wenbin Xiao James R Cook Source Type: research
Progression of Hodgkin lymphoma and plasma cell neoplasms: Report from the 2021 SH/EAHP Workshop
CONCLUSIONS: Better molecular characterization of both of these neoplasms and mechanisms of progression will help us to better understand mechanisms of progression and perhaps develop better prognostic models, as well as identifying novel therapeutic targets.PMID:37085150 | DOI:10.1093/ajcp/aqad023 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - April 21, 2023 Category: Cancer & Oncology Authors: Reza Nejati Catalina Amador Magdalena Czader Elizabeth Thacker Devang Thakkar Sandeep S Dave Ahmet Dogan Amy Duffield John R Goodlad German Ott Mariusz A Wasik Wenbin Xiao James R Cook Source Type: research
SOHO State-of-the-Art Updates and Next Questions: A Modern Approach to the Systemic Treatment of Advanced CTCL
Clin Lymphoma Myeloma Leuk. 2023 Mar 17:S2152-2650(23)00088-5. doi: 10.1016/j.clml.2023.03.003. Online ahead of print.ABSTRACTThe term cutaneous T-cell lymphoma (CTCL) is a general term for T-cell lymphomas that are found primarily in skin. The most common CTCL entities, mycosis fungoides and Sezary syndrome are incurable diseases with a plethora of conventional treatment options. In the past treatment options have been selected primarily according to stage. Given newer targeted therapies with varied response in different body compartments, we suggest a compartment-guided algorithm that may enhance response rates directing...
Source: Clinical Lymphoma and Myeloma - April 15, 2023 Category: Cancer & Oncology Authors: Danielle Brazel Lauren Pinter-Brown Source Type: research
Impact of Disease Progression, Line of Therapy, and Response on Health-Related Quality of Life in Multiple Myeloma: A Systematic Literature Review
Clin Lymphoma Myeloma Leuk. 2023 Mar 18:S2152-2650(23)00091-5. doi: 10.1016/j.clml.2023.03.005. Online ahead of print.ABSTRACTThis systematic literature review (SLR) was conducted to better understand the impact of disease progression, line of therapy, and clinical response on health-related quality of life (HRQoL) in patients with multiple myeloma (MM). Multiple databases were searched to identify records relating to HRQoL in adult patients with MM. Titles and abstracts were independently screened by 2 reviewers for inclusion based on pre-defined criteria. Records flagged for inclusion had full texts subsequently screened...
Source: Clinical Lymphoma and Myeloma - April 15, 2023 Category: Cancer & Oncology Authors: Rafael Fonseca Diana Tran Alyshia Laidlaw Emily Rosta Manvir Rai Joana Duran Eric M Ammann Source Type: research
SOHO State-of-the-Art Updates and Next Questions: A Modern Approach to the Systemic Treatment of Advanced CTCL
Clin Lymphoma Myeloma Leuk. 2023 Mar 17:S2152-2650(23)00088-5. doi: 10.1016/j.clml.2023.03.003. Online ahead of print.ABSTRACTThe term cutaneous T-cell lymphoma (CTCL) is a general term for T-cell lymphomas that are found primarily in skin. The most common CTCL entities, mycosis fungoides and Sezary syndrome are incurable diseases with a plethora of conventional treatment options. In the past treatment options have been selected primarily according to stage. Given newer targeted therapies with varied response in different body compartments, we suggest a compartment-guided algorithm that may enhance response rates directing...
Source: Clinical Lymphoma and Myeloma - April 15, 2023 Category: Cancer & Oncology Authors: Danielle Brazel Lauren Pinter-Brown Source Type: research
Impact of Disease Progression, Line of Therapy, and Response on Health-Related Quality of Life in Multiple Myeloma: A Systematic Literature Review
Clin Lymphoma Myeloma Leuk. 2023 Mar 18:S2152-2650(23)00091-5. doi: 10.1016/j.clml.2023.03.005. Online ahead of print.ABSTRACTThis systematic literature review (SLR) was conducted to better understand the impact of disease progression, line of therapy, and clinical response on health-related quality of life (HRQoL) in patients with multiple myeloma (MM). Multiple databases were searched to identify records relating to HRQoL in adult patients with MM. Titles and abstracts were independently screened by 2 reviewers for inclusion based on pre-defined criteria. Records flagged for inclusion had full texts subsequently screened...
Source: Clinical Lymphoma and Myeloma - April 15, 2023 Category: Cancer & Oncology Authors: Rafael Fonseca Diana Tran Alyshia Laidlaw Emily Rosta Manvir Rai Joana Duran Eric M Ammann Source Type: research
SOHO State-of-the-Art Updates and Next Questions: A Modern Approach to the Systemic Treatment of Advanced CTCL
Clin Lymphoma Myeloma Leuk. 2023 Mar 17:S2152-2650(23)00088-5. doi: 10.1016/j.clml.2023.03.003. Online ahead of print.ABSTRACTThe term cutaneous T-cell lymphoma (CTCL) is a general term for T-cell lymphomas that are found primarily in skin. The most common CTCL entities, mycosis fungoides and Sezary syndrome are incurable diseases with a plethora of conventional treatment options. In the past treatment options have been selected primarily according to stage. Given newer targeted therapies with varied response in different body compartments, we suggest a compartment-guided algorithm that may enhance response rates directing...
Source: Clinical Lymphoma and Myeloma - April 15, 2023 Category: Cancer & Oncology Authors: Danielle Brazel Lauren Pinter-Brown Source Type: research
Impact of Disease Progression, Line of Therapy, and Response on Health-Related Quality of Life in Multiple Myeloma: A Systematic Literature Review
Clin Lymphoma Myeloma Leuk. 2023 Mar 18:S2152-2650(23)00091-5. doi: 10.1016/j.clml.2023.03.005. Online ahead of print.ABSTRACTThis systematic literature review (SLR) was conducted to better understand the impact of disease progression, line of therapy, and clinical response on health-related quality of life (HRQoL) in patients with multiple myeloma (MM). Multiple databases were searched to identify records relating to HRQoL in adult patients with MM. Titles and abstracts were independently screened by 2 reviewers for inclusion based on pre-defined criteria. Records flagged for inclusion had full texts subsequently screened...
Source: Clinical Lymphoma and Myeloma - April 15, 2023 Category: Cancer & Oncology Authors: Rafael Fonseca Diana Tran Alyshia Laidlaw Emily Rosta Manvir Rai Joana Duran Eric M Ammann Source Type: research
SOHO State-of-the-Art Updates and Next Questions: A Modern Approach to the Systemic Treatment of Advanced CTCL
Clin Lymphoma Myeloma Leuk. 2023 Mar 17:S2152-2650(23)00088-5. doi: 10.1016/j.clml.2023.03.003. Online ahead of print.ABSTRACTThe term cutaneous T-cell lymphoma (CTCL) is a general term for T-cell lymphomas that are found primarily in skin. The most common CTCL entities, mycosis fungoides and Sezary syndrome are incurable diseases with a plethora of conventional treatment options. In the past treatment options have been selected primarily according to stage. Given newer targeted therapies with varied response in different body compartments, we suggest a compartment-guided algorithm that may enhance response rates directing...
Source: Clinical Lymphoma and Myeloma - April 15, 2023 Category: Cancer & Oncology Authors: Danielle Brazel Lauren Pinter-Brown Source Type: research
Impact of Disease Progression, Line of Therapy, and Response on Health-Related Quality of Life in Multiple Myeloma: A Systematic Literature Review
Clin Lymphoma Myeloma Leuk. 2023 Mar 18:S2152-2650(23)00091-5. doi: 10.1016/j.clml.2023.03.005. Online ahead of print.ABSTRACTThis systematic literature review (SLR) was conducted to better understand the impact of disease progression, line of therapy, and clinical response on health-related quality of life (HRQoL) in patients with multiple myeloma (MM). Multiple databases were searched to identify records relating to HRQoL in adult patients with MM. Titles and abstracts were independently screened by 2 reviewers for inclusion based on pre-defined criteria. Records flagged for inclusion had full texts subsequently screened...
Source: Clinical Lymphoma and Myeloma - April 15, 2023 Category: Cancer & Oncology Authors: Rafael Fonseca Diana Tran Alyshia Laidlaw Emily Rosta Manvir Rai Joana Duran Eric M Ammann Source Type: research
SOHO State-of-the-Art Updates and Next Questions: A Modern Approach to the Systemic Treatment of Advanced CTCL
Clin Lymphoma Myeloma Leuk. 2023 Mar 17:S2152-2650(23)00088-5. doi: 10.1016/j.clml.2023.03.003. Online ahead of print.ABSTRACTThe term cutaneous T-cell lymphoma (CTCL) is a general term for T-cell lymphomas that are found primarily in skin. The most common CTCL entities, mycosis fungoides and Sezary syndrome are incurable diseases with a plethora of conventional treatment options. In the past treatment options have been selected primarily according to stage. Given newer targeted therapies with varied response in different body compartments, we suggest a compartment-guided algorithm that may enhance response rates directing...
Source: Clinical Lymphoma and Myeloma - April 15, 2023 Category: Cancer & Oncology Authors: Danielle Brazel Lauren Pinter-Brown Source Type: research
Impact of Disease Progression, Line of Therapy, and Response on Health-Related Quality of Life in Multiple Myeloma: A Systematic Literature Review
Clin Lymphoma Myeloma Leuk. 2023 Mar 18:S2152-2650(23)00091-5. doi: 10.1016/j.clml.2023.03.005. Online ahead of print.ABSTRACTThis systematic literature review (SLR) was conducted to better understand the impact of disease progression, line of therapy, and clinical response on health-related quality of life (HRQoL) in patients with multiple myeloma (MM). Multiple databases were searched to identify records relating to HRQoL in adult patients with MM. Titles and abstracts were independently screened by 2 reviewers for inclusion based on pre-defined criteria. Records flagged for inclusion had full texts subsequently screened...
Source: Clinical Lymphoma and Myeloma - April 15, 2023 Category: Cancer & Oncology Authors: Rafael Fonseca Diana Tran Alyshia Laidlaw Emily Rosta Manvir Rai Joana Duran Eric M Ammann Source Type: research
SOHO State-of-the-Art Updates and Next Questions: A Modern Approach to the Systemic Treatment of Advanced CTCL
Clin Lymphoma Myeloma Leuk. 2023 Mar 17:S2152-2650(23)00088-5. doi: 10.1016/j.clml.2023.03.003. Online ahead of print.ABSTRACTThe term cutaneous T-cell lymphoma (CTCL) is a general term for T-cell lymphomas that are found primarily in skin. The most common CTCL entities, mycosis fungoides and Sezary syndrome are incurable diseases with a plethora of conventional treatment options. In the past treatment options have been selected primarily according to stage. Given newer targeted therapies with varied response in different body compartments, we suggest a compartment-guided algorithm that may enhance response rates directing...
Source: Clinical Lymphoma and Myeloma - April 15, 2023 Category: Cancer & Oncology Authors: Danielle Brazel Lauren Pinter-Brown Source Type: research
Impact of Disease Progression, Line of Therapy, and Response on Health-Related Quality of Life in Multiple Myeloma: A Systematic Literature Review
Clin Lymphoma Myeloma Leuk. 2023 Mar 18:S2152-2650(23)00091-5. doi: 10.1016/j.clml.2023.03.005. Online ahead of print.ABSTRACTThis systematic literature review (SLR) was conducted to better understand the impact of disease progression, line of therapy, and clinical response on health-related quality of life (HRQoL) in patients with multiple myeloma (MM). Multiple databases were searched to identify records relating to HRQoL in adult patients with MM. Titles and abstracts were independently screened by 2 reviewers for inclusion based on pre-defined criteria. Records flagged for inclusion had full texts subsequently screened...
Source: Clinical Lymphoma and Myeloma - April 15, 2023 Category: Cancer & Oncology Authors: Rafael Fonseca Diana Tran Alyshia Laidlaw Emily Rosta Manvir Rai Joana Duran Eric M Ammann Source Type: research
Immune Reconstitution and Vaccinations in Multiple Myeloma: A Report From the 19th International Myeloma Society Annual Workshop
Clin Lymphoma Myeloma Leuk. 2023 Mar 23:S2152-2650(23)00106-4. doi: 10.1016/j.clml.2023.03.009. Online ahead of print.ABSTRACTGiven the significance of the immune system and the important role of therapies within the context of the immune system in plasma cell disorders, the International Myeloma Society annual workshop convened a session dedicated to this topic. A panel of experts covered various aspects of immune reconstitution and vaccination. The top oral presentations were highlighted and discussed. This is a report of the proceedings.PMID:37055346 | DOI:10.1016/j.clml.2023.03.009 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - April 13, 2023 Category: Cancer & Oncology Authors: Evangelos Terpos Paola Neri Niels W C J van de Donk Mattia D'Agostino Samir Parekh Sundar Jagannath Heinz Ludwig David E Avigan Madhav V Dhodapkar Noopur S Raje Source Type: research
